# Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome

> **NCT04185220** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 6 (actual)

## Conditions studied

- Adult T-Cell Lymphoma/Leukemia
- Sezary Syndrome
- Mycosis Fungoides

## Interventions

- **DRUG:** Recombinant human Interleukin-15 (rhIL-15)
- **BIOLOGICAL:** Mogamulizumab

## Key facts

- **NCT ID:** NCT04185220
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-26
- **Primary completion:** 2020-11-06
- **Final completion:** 2022-05-18
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04185220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04185220, "Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04185220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*